BRPI0600285C1 - compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas - Google Patents
compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticasInfo
- Publication number
- BRPI0600285C1 BRPI0600285C1 BRC10600285-4A BRPI0600285A BRPI0600285C1 BR PI0600285 C1 BRPI0600285 C1 BR PI0600285C1 BR PI0600285 A BRPI0600285 A BR PI0600285A BR PI0600285 C1 BRPI0600285 C1 BR PI0600285C1
- Authority
- BR
- Brazil
- Prior art keywords
- lipid
- analogs
- pharmaceutical compounds
- nanostructures
- paclitaxel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
COMPOSTOS FARMACêUTICOS CONTENDO NANOPARTìCULAS úTEIS PARA TRATAMENTO DE LESõES REESTENóTICAS. São descritas compostos farmacêuticos contendo nanoestruturas lipídicas carreadoras de rapamicina ou análogos, paclitaxel ou análogos, ou a combinação de rapamicina ou análogos e paclitaxel ou análogos úteis para a estabilização (não progressão) ou redução da placa ateromatosa e para a prevenção e tratamento da reestenose intra-stent, assim como de outras doenças e processos biológicos caracterizados pela proliferação celular aumentada e/ou desordenada, sendo as nanoestrutu ras lipídicas selecionadas dentre lipoproteinas LDL e/ou VLDL associadas ou não a componentes lipídicos compatíveis com a administração intravenosa como fosfatidilcolina, fosfolipideos, lecitinas, colesterol e seus ésteres, e triacilgliceróis, em que as lipoproteinas plasmáticas são livres, acetiladas ou oxidadas. Essas nanoestruturas lipídicas compreendem nanoemu Isões, lipossomas de dimensões nanométricas, carreadores lipídicos nanoestruturados, nanopartículas lipídicas sólidas, e/ou similares.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRC10600285-4A BRPI0600285C1 (pt) | 2006-01-13 | 2006-01-13 | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
CNA2007800017443A CN101365447A (zh) | 2006-01-13 | 2007-01-12 | 用于治疗再狭窄病变的含有纳米粒子的药物组合物 |
AU2007204550A AU2007204550A1 (en) | 2006-01-13 | 2007-01-12 | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions |
EP07701600A EP1978957A4 (en) | 2006-01-13 | 2007-01-12 | NANOTEILS CONTAINING PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF RESTENOTIC LESIONS |
JP2008549721A JP2009523133A (ja) | 2006-01-13 | 2007-01-12 | 再狭窄病変治療に有用なナノ粒子含有の薬化合物類 |
CA002636336A CA2636336A1 (en) | 2006-01-13 | 2007-01-12 | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions |
PCT/BR2007/000015 WO2007079560A2 (en) | 2006-01-13 | 2007-01-12 | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions |
US12/217,028 US20090011005A1 (en) | 2006-01-13 | 2008-07-01 | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRC10600285-4A BRPI0600285C1 (pt) | 2006-01-13 | 2006-01-13 | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0600285A BRPI0600285A (pt) | 2007-10-02 |
BRPI0600285C1 true BRPI0600285C1 (pt) | 2011-10-11 |
Family
ID=38256650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRC10600285-4A BRPI0600285C1 (pt) | 2006-01-13 | 2006-01-13 | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090011005A1 (pt) |
EP (1) | EP1978957A4 (pt) |
JP (1) | JP2009523133A (pt) |
CN (1) | CN101365447A (pt) |
AU (1) | AU2007204550A1 (pt) |
BR (1) | BRPI0600285C1 (pt) |
CA (1) | CA2636336A1 (pt) |
WO (1) | WO2007079560A2 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
WO2008063576A2 (en) * | 2006-11-20 | 2008-05-29 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
WO2011139899A2 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
KR101314579B1 (ko) * | 2011-04-07 | 2013-10-10 | 광주과학기술원 | 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법 |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
CN114028623B (zh) * | 2021-10-26 | 2024-02-27 | 江苏朴芃医疗科技有限公司 | 心脏分流器 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
IL139541A0 (en) * | 1998-05-20 | 2004-02-08 | Liposome Co Inc | Novel particulate formulations |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US20030065382A1 (en) * | 2001-10-02 | 2003-04-03 | Fischell Robert E. | Means and method for the treatment of coronary artery obstructions |
US20050095267A1 (en) * | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
EP1608359A4 (en) * | 2003-04-03 | 2011-08-17 | Jessie L-S Au | DRUG-LOADING PARTICLES TARGETING TUMORS |
EP1628641A2 (en) * | 2003-05-19 | 2006-03-01 | Baxter International Inc. | Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
US8043631B2 (en) * | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
JP2008512350A (ja) * | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
US7727554B2 (en) * | 2004-12-21 | 2010-06-01 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Sustained-release nanoparticle compositions and methods for using the same |
US20060257450A1 (en) * | 2005-03-21 | 2006-11-16 | Sreenivasu Mudumba | Drug delivery systems for treatment of diseases or conditions |
-
2006
- 2006-01-13 BR BRC10600285-4A patent/BRPI0600285C1/pt active Search and Examination
-
2007
- 2007-01-12 CA CA002636336A patent/CA2636336A1/en not_active Abandoned
- 2007-01-12 JP JP2008549721A patent/JP2009523133A/ja active Pending
- 2007-01-12 WO PCT/BR2007/000015 patent/WO2007079560A2/en active Application Filing
- 2007-01-12 AU AU2007204550A patent/AU2007204550A1/en not_active Abandoned
- 2007-01-12 EP EP07701600A patent/EP1978957A4/en not_active Withdrawn
- 2007-01-12 CN CNA2007800017443A patent/CN101365447A/zh active Pending
-
2008
- 2008-07-01 US US12/217,028 patent/US20090011005A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090011005A1 (en) | 2009-01-08 |
AU2007204550A1 (en) | 2007-07-19 |
WO2007079560A3 (en) | 2007-12-27 |
WO2007079560A2 (en) | 2007-07-19 |
CN101365447A (zh) | 2009-02-11 |
JP2009523133A (ja) | 2009-06-18 |
BRPI0600285A (pt) | 2007-10-02 |
EP1978957A2 (en) | 2008-10-15 |
EP1978957A4 (en) | 2013-01-09 |
CA2636336A1 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0600285C1 (pt) | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas | |
Chen et al. | Antibacterial micelles with vancomycin-mediated targeting and pH/lipase-triggered release of antibiotics | |
Jia et al. | Nanotoxicity of different sizes of graphene (G) and graphene oxide (GO) in vitro and in vivo | |
Durán et al. | Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity | |
Habiba et al. | Synergistic antibacterial activity of PEGylated silver–graphene quantum dots nanocomposites | |
Sun et al. | Graphene quantum dots-band-aids used for wound disinfection | |
Phenrat et al. | Partial oxidation (“aging”) and surface modification decrease the toxicity of nanosized zerovalent iron | |
Zhao et al. | Synergy of non-antibiotic drugs and pyrimidinethiol on gold nanoparticles against superbugs | |
Bohanon et al. | Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis | |
Liu et al. | Graphene oxide attenuates the cytotoxicity and mutagenicity of PCB 52 via activation of genuine autophagy | |
BR112012010270A2 (pt) | mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco | |
Xue et al. | Alkaline “nanoswords” coordinate ferroptosis-like bacterial death for antibiosis and osseointegration | |
BRPI0519890A2 (pt) | macrociclos de 18 elementos e seus análogos | |
BR112014029010A2 (pt) | sistemas para tratamento de infecções pulmonares | |
BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
Xiaoli et al. | Graphene oxide disrupted mitochondrial homeostasis through inducing intracellular redox deviation and autophagy-lysosomal network dysfunction in SH-SY5Y cells | |
Zolali et al. | Effects of gamma oryzanol on factors of oxidative stress and sepsis-induced lung injury in experimental animal model | |
Singh et al. | MoS2-modified curcumin nanostructures: the novel theranostic hybrid having potent antibacterial and antibiofilm activities against multidrug-resistant hypervirulent klebsiella pneumoniae | |
Al-Hakkani et al. | Environmentally azithromycin pharmaceutical wastewater management and synergetic biocompatible approaches of loaded azithromycin@ hematite nanoparticles | |
Cui et al. | Bis (12)-hupyridone, a novel acetylcholinesterase inhibitor, protects against glutamate-induced neuronal excitotoxicity via activating α7 nicotinic acetylcholine receptor/phosphoinositide 3-kinase/Akt cascade | |
Chavez-Dozal et al. | In vitro analysis of flufenamic acid activity against Candida albicans biofilms | |
Zhong et al. | Development of amphiphilic coumarin derivatives as membrane-active antimicrobial agents with potent in vivo efficacy against Gram-positive pathogenic bacteria | |
Qian et al. | Roles and current applications of S-nitrosoglutathione in anti-infective biomaterials | |
Gu et al. | Dihydroartemisinin-loaded chitosan nanoparticles inhibit the rifampicin-resistant mycobacterium tuberculosis by disrupting the cell wall | |
Zhang et al. | Long-term antibacterial activity of guanidinium carbon dots without detectable resistance for the effective treatment of pneumonia caused by Gram-negative bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
B11Q | Dismissal: the certificate of addition was not accessory to any patent, or a patent which was nominated accessory and no longer exists |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |